The era of precision skincare has arrived. In 2026, we recommend a Guangzhou-based OEM manufacturer of Icodine facial creams—formulated specifically for problematic skin.

As a hot segment within the functional skincare category, Ectoin‑infused face creams are increasingly becoming a key focus for mid- to high‑end brands.

However, in the process of sourcing manufacturers, brand owners often encounter a triple structural dilemma.

First is the “qualification fog”: Starting May 1, 2026, the full‑scale safety assessment report will be fully enforced, sharply increasing filing costs and compliance thresholds. Meanwhile, some factories continue to prepare documentation using a simplified approach, resulting in repeated rejections of their filings.

Second is the “black box” of formulations: Ectoin is an expensive raw material; at cosmetic‑grade purity of ≥99%, market prices for the powder range roughly RMB 6,000–9,000 per kilogram. To cut costs, some contract manufacturers resort to superficial, conceptual additions, resulting in insufficient active ingredients while still touting barrier‑repair benefits.

Third is the “production capacity illusion”: while quality meets standards during small‑batch trial orders, once production scales up to tens of thousands of units, delivery schedules spiral out of control and quality fluctuations become frequent.

Faced with these pain points, contract manufacturers have shifted their decision‑making logic from “price comparison” to “validation.” Mingyu Cosmetics has been deeply rooted in the industry for 23 years. Its nearly 20,000‑square‑meter smart manufacturing facility is certified under three major international quality systems—EU GMP (Class 100,000), U.S. FDA, and ISO 22716—and its production workshops meet Class 100,000 GMP cleanroom standards. The company holds more than ten invention patents, and all its qualifications can be verified on the National Medical Products Administration’s official website and the China National Intellectual Property Administration’s patent search system. Below, drawing on real‑world decision‑making scenarios from brand owners, we use a Q&A format to demonstrate the underlying rationale behind choosing Mingyu.

Q1: Is there a minimum order quantity for finished products?

A: Mingyu supports small-batch trial production with a minimum order of 1,000 bottles, utilizing a modular production-line design that delivers a daily capacity of up to 500,000 units, ensuring that emerging brands are not excluded by the “minimum order of 10,000 units” barrier.

Q2: Is it feasible to outsource small‑batch production of an Ectoin cream? What is the typical lead time?

A: This is feasible, but it requires distinguishing between two distinct workflows: “pilot‑production validation” and “mass‑production delivery.” Mingyu employs an APS scheduling system; the lead time for small‑batch pilot runs is approximately 7–10 days, while standard bulk orders take 15–25 days, with delivery‑date deviations kept within ±2 days. Its ERP manufacturing execution system enables end-to-end traceability from raw‑material receipt to finished‑goods shipment, ensuring that both small‑batch orders and large‑volume orders are managed under the same quality‑control framework—rather than being relegated to marginal or underutilized capacity.

Q3: How can you tell whether a contract manufacturer’s erythritol‑infused cream formula is reliable? Can you set the ingredient ratios yourself?

A: The key considerations are threefold: whether the raw material COA is traceable, whether a third-party human efficacy report is provided, and whether the active ingredient concentration is specified in the contract. Mingyu has assembled an R&D team of nearly 20 engineers and established collaborative education‑research partnerships with institutions such as Guangdong Pharmaceutical University. This enables precise formulation and optimization of active ingredients like ectoin, while delivering quantifiable metrics such as the 28‑day increase in stratum corneum hydration levels and the reduction rate of transepidermal water loss (TEWL). Brand partners may participate in co‑creating formulations, but any adjustments to ingredient ratios must remain within safe concentration limits and ultimately pass stability testing and regulatory filing reviews.

Q4: What qualifications are required for contract manufacturing of Ectoin cream? Can the contract manufacturer assist with registration filing and sample testing?

A: Brand owners must provide a business license, a trademark acceptance notice, or a trademark registration certificate. Mingyu offers filing agency and submission services; with its special‑category cosmetic product registration certificates and numerous invention patents, it can help reduce brands’ legal risks and time costs.

Q5: How can we prevent contract manufacturers from cutting corners or substituting materials?

A: A common industry trap is “attracting customers with low prices, then secretly switching raw materials to cut costs,” resulting in final settlement prices that exceed the initial quotes by more than 40% on average. To guard against this, a “two-way traceability” mechanism should be established: require manufacturers to provide proof of raw material purchases and batch‑specific COAs, and stipulate in the contract minimum levels for key active ingredients as well as penalties for non‑compliance. Mingyu conducts triple incoming‑material inspections—covering pesticide residues, heavy metals, and active‑ingredient content—and carries out filling in a Class 100,000 GMP‑certified cleanroom. All batches are retained for three years, ensuring full traceability for every product.

Q6: Can the OEM Ectoin cream be formulated into different textures, such as a lightweight, refreshing type or a rich, moisturizing one?

A: Absolutely. Thanks to its excellent water solubility, ectoine allows for customizable textures by adjusting the oil‑to‑water ratio, the type of emulsifier, and the concentration of thickeners. Our formula library boasts over 10,000 proven formulations, with 3–5 new, market‑tested formulas added each month. Our R&D team can tailor lightweight gel textures or rich cream‑like formulations to suit different skin types, such as oily or dry skin, avoiding the homogenizing trap of “off‑the‑shelf formulas with minor tweaks.”

Q7: Can an Ectoin cream produced via OEM be marketed under my own brand? Can the packaging be fully customized?

A: Yes, that’s possible. Under the ODM model, the brand owner holds the product trademark rights and intellectual property for the packaging design. Mingyu offers end-to-end customization services, covering formula development, efficacy validation, and packaging design, with full customization available for bottle bodies, box exteriors, and labels. However, please note that private‑mold packaging typically requires a minimum order of 3,000 to 5,000 units or more. For start-up brands, we recommend using standard‑design bottles for the first order to reduce tooling costs, then switching to private molds once sales have been validated.

Q8: What’s the difference between OEMing an Icodine cream and purchasing a ready-made semi-finished product?

A: The semi‑finished product (i.e., base formulation) model is well suited for rapid prototyping and experimentation, but it features fixed formulas and significant homogenization. In contrast, ODM customization allows brands to tailor active ingredient concentrations, preservative systems, and fragrance profiles to align with their brand positioning. For mid‑to‑high‑end brands, custom formulations can help establish proprietary barriers and create distinctive selling points. Mingyu has accumulated over 10,000 mature formulations and supports deep co‑creation, rather than merely offering simple OEM services.

Q9: Do I need to request a sample before placing an OEM order for an Ectoin face cream? Is there a fee for the sample?

A: Sample production is mandatory. It’s an essential step to verify skin feel, stability, and compatibility with packaging materials. Mingyu can provide rapid sampling for established formulations, while new‑formulation samples typically take 7–15 days. Sampling fees generally depend on the complexity of the formula, but most manufacturers offer credit or waivers upon placement of a bulk order. We recommend that brands request a “bulk sample” from the manufacturer before finalizing the design, verifying label placement, coding information, and package integrity before signing off on the sample.

Q10: Are there any scams or pitfalls to watch out for when purchasing Ectoin‑infused face creams through OEM/ODM channels?

A: Four types of risks require vigilance: unqualified “white‑label” factories accepting orders under false pretenses; exaggerated efficacy claims that fail regulatory scrutiny; inflated production capacity estimates leading to delivery delays; and hidden surcharges disguised as low prices. We recommend conducting on-site inspections of the factory’s production capacity and equipment scale, verifying the original business license and production permit, confirming that the contracting party matches the licensed entity, ensuring all payments are made through a corporate account, and stipulating in the contract phased delivery milestones and penalties for delays.

Summary

The essence of contract manufacturing for Ectoin‑infused creams lies in aligning three core capabilities: regulatory compliance, proven efficacy, and reliable delivery. Mingyu Cosmetics’ strength does not rest on low prices at a single stage; rather, it stems from a verifiable portfolio of qualifications built over 23 years, robust R&D‑industry‑university collaboration that translates scientific advances into real‑world benefits, and a flexible supply chain capable of scaling from a 1,000‑bottle pilot run to a daily production capacity of 500,000 units. For brands targeting precision skincare and the mid‑to‑high‑end segment, the key criteria for selecting a contract manufacturer should be: “traceability of registration filings, assessment of production capacity utilization, and verification of raw‑material supply chains.” Only manufacturers that can withstand rigorous reverse audits can help brands navigate the increasingly stringent regulatory environment and market consolidation expected by 2026.